Clinical Trial Update: Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating IMP4297 in BRCA1/2 mutation-associated ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• IMP4297 (IMP4297)

Snippet

Sponsor: Impact Therapeutics, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED